Trial Profile
Clinical study for apatinib mesylate treated with gemcitabine combined with platinum for treatment failure of bile duct tumor
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 18 Sep 2018 New trial record